The CEA Registry Blog

By CEA Registry Team on 2/24/2015 12:02 PM

By James Chambers, Ph.D.

US payers make coverage and reimbursement decisions for drugs upon their FDA approval.  These decisions are made before the supporting evidence has fully matured, and typically before cost-effectiveness evidence is available.  This lag between FDA approval and publication of cost-effectiveness evidence can hamper payers from accounting for value in coverage and reimbursement decisions. 

In a new paper, published as a special report in Expert Review of Pharmacoeconomics and Outcomes Research, we examined this lag, and whether it has changed over time.(1)  For drugs approved for the first time by the FDA from 2000 through 2010, we searched the CEA Registry (www.cearegistry.org) for relevant cost-utility analyses (CUAs), and for each identified study we determined the date of first publication.  Then, for each drug, we determined whether a CUA was published in the three years following FDA approval.  We used a 3-year period as this was the maximum interval between the most recently approved drug in the dataset and the end of the search period.

Of all drugs approved in our time period, 23% (62/274) were associated with a CUA within the three years following approval.  The lag before CUA publication has decreased over time, and compared with drugs approved from 2000 to 2003, the lag was shorter for drugs approved from 2004 to 2006 (p=0.06), and from 2007 to 2010 (p<0.01) (Figure 1).

Our findings are encouraging, and illustrate that payers now have somewhat more rapid access to evidence of value than they did previously.  Nevertheless, we found that many drugs did not have an accompanying CUA, and of those that did, there was still a lengthy delay for several before the study was available.  We are hopeful that, as demand for evidence of value grows, the lag between FDA approval and publication of a CUA will decrease further.  



1.    Chambers JD, Thorat T, Pyo J, Neumann PJ. The lag from FDA approval to published cost-utility evidence. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 12:1-4

By CEA Registry Team on 2/18/2015 2:53 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials

1: Slaman J, van den Berg-Emons R, Tan SS, et. al. Cost-utility of a lifestyle intervention in adolescents and young adults with spastic cerebral palsy. J Rehabil Med. 2015 Feb 12. [Epub ahead of print] PubMed PMID: 25678311.

2: Leidner AJ, Chesson HW, Xu F, et. al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25677072.

3: Ball S, Vickery J, Hobart J, et. al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015 Feb;19(12):1-188. PubMed PMID: 25676540.

4: Lao C, Brown C, Rouse P, et. al. Economic evaluation of prostate cancer screening: a systematic review. Future Oncol. 2015 Feb;11(3):467-77. PubMed PMID: 25675126.

5: Zhang C, Ke W, Gao Y, et. al. Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China. Clin Drug Investig. 2015 Feb 12. [Epub ahead of print] PubMed PMID: 25672930.

6: Gyrd-Hansen D, Olsen KR, Bollweg K, et. al. Cost-effectiveness estimate of prehospital thrombolysis: Results of the PHANTOM-S Study. Neurology. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25672925.

7: Alberti A, Giudice P, Gelera A, et. al. Understanding the economic impact of intravascular ultrasound (IVUS). Eur J Health Econ. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25669755.

8: Retèl VP, van der Molen L, Steuten LM, et. al. A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. Eur Arch Otorhinolaryngol. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25666587.

9: Spolverato G, Vitale A, Ejaz A, et. al. The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World J Surg. 2015 Feb 10. [Epub ahead of print] PubMed PMID: 25665675.

10: Bouland AJ, Risko N, Lawner BJ, et. al. The Price of a Helping Hand: Modeling the Outcomes and Costs of Bystander CPR. Prehosp Emerg Care. 2015 Feb 9. [Epub ahead of print] PubMed PMID: 25665010.

11: Stevens KJ. How Well Do the Generic Multi-attribute Utility Instruments Incorporate Patient and Public Views Into Their Descriptive Systems? Patient. 2015 Feb 8. [Epub ahead of print] PubMed PMID: 25663152.

12: Tao L, Wilson EC, Wareham NJ, et. al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med. 2015 Feb 6. [Epub ahead of print] PubMed PMID: 25661661.

13: Cowper PA, Pan W, Anstrom KJ, et. al. Economic Analysis of Ticagrelor Therapy From a U.S. Perspective: Results From the PLATO Study. J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. PubMed PMID: 25660925.

14: Song DL, Altice FL, Copenhaver MM, et. al. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLoS One. 2015 Feb 6;10(2):e0116694. eCollection 2015. PubMed PMID: 25658949.

15: Fergenbaum J, Bermingham S, Krahn M, et. al. Care in the Home for the Management of Chronic Heart Failure: Systematic Review and Cost-Effectiveness Analysis. J Cardiovasc Nurs. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25658188.

16: Saret CJ, Winn A, Shah G, et. al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25655601.

17: Rubio-Terrés C, Soria JM, Morange PE, et. al. Economic Analysis of Thrombo inCode, a Clinical-Genetic Function for Assessing the Risk of Venous Thromboembolism. Appl Health Econ Health Policy. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25652150.

18: Tuffaha HW, Roberts S, Chaboyer W, et. al. Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later. Appl Health Econ Health Policy. 2015 Feb 4. [Epub ahead of print] PubMed PMID: 25650349.

19: Chandra A, Snider JT, Wu Y, et. al. Robot-assisted surgery for kidney cancer increased access to a procedure that can reduce mortality and renal failure. Health Aff (Millwood). 2015 Feb 1;34(2):220-8. PubMed PMID: 25646101.

20: Okubo R, Kondo M, Hoshi SL, et. al. Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease. Sleep Breath. 2015 Feb 3. [Epub ahead of print] PubMed PMID: 25643768.

21: Borisenko O, Adam D, Funch-Jensen P, et. al. Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. Obes Surg. 2015 Feb 2. [Epub ahead of print] PubMed PMID: 25639648.

22: Scalone L, Cortesi PA. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate quality-adjusted life-years. BioDrugs. 2015 Feb;29(1):69. PubMed PMID: 25633571.

23: Kazerooni R, Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am J Health Syst Pharm. 2015 Feb 15;72(4):301-7. PubMed PMID: 25631837.

24: Zachariah JP, Samnaliev M. Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model. J Med Econ. 2015 Feb 9:1-10. [Epub ahead of print] PubMed PMID: 25629653.

25: Al Hussein Al Awamlh B, Lee R, Chughtai B, et. al. A Cost-effectiveness Analysis of Management of Low-risk Non-muscle-invasive Bladder Cancer Using Office-based Fulguration. Urology. 2015 Feb;85(2):381-7. PubMed PMID: 25623694.

26: Tanaka E, Inoue E, Hoshi D, et. al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol. 2015 Feb 11:1-11. [Epub ahead of print] PubMed PMID: 25547018.

27: Sawyer LM, Wonderling D, Jackson K, et. al. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. Pharmacoeconomics. 2015 Feb;33(2):163-77. PubMed PMID: 25526841.

28: Kongnakorn T, Lanitis T, Annemans L, et. al. Stroke and systemic embolism prevention in patients with atrial fibrillation in belgium: comparative cost effectiveness of new oral anticoagulants and warfarin. Clin Drug Investig. 2015 Feb;35(2):109-19. PubMed PMID: 25511639.

29: Aballéa S, Maman K, Thokagevistk K, et. al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United kingdom. Clin Drug Investig. 2015 Feb;35(2):83-93. PubMed PMID: 25491433.

30: Nord E. Cost-value analysis of health interventions: introduction and update on methods and preference data. Pharmacoeconomics. 2015 Feb;33(2):89-95. PubMed PMID: 25488879.

31: Sprague BL, Stout NK, Schechter C, et. al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015 Feb 3;162(3):157-66. PubMed PMID: 25486550.

32: Rajan S, Baraniuk S, Parker S, et. al. Implementing a mobile stroke unit program in the United States: why, how, and how much? JAMA Neurol. 2015 Feb 1;72(2):229-34. PubMed PMID: 25485723.

33: Blank PR, Filipits M, Dubsky P, et. al. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics. 2015 Feb;33(2):179-90. PubMed PMID: 25404424.

34: Hsieh HM, Tsai SL, Shin SJ, et. al. Cost-Effectiveness of Diabetes Pay-for-Performance Incentive Designs. Med Care. 2015 Feb;53(2):106-15. PubMed PMID: 25397966.

35: Huh WK, Williams E, Huang J, et. al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy. 2015 Feb;13(1):95-107. PubMed PMID: 25385310.

36: Ziakas PD, Zacharioudakis IM, Zervou FN, et. al. Methicillin-Resistant Staphylococcus aureus Prevention Strategies in the ICU: A Clinical Decision Analysis*. Crit Care Med. 2015 Feb;43(2):382-93. PubMed PMID: 25377019.

37: McEwan P, Bennett H, Ward T, et. al. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. Pharmacoeconomics. 2015 Feb;33(2):149-61. PubMed PMID: 25344660.

38: Greenhalgh J, Bagust A, Boland A, et. al. Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics. 2015 Feb;33(2):137-48. PubMed PMID: 25213036.

39: Rognoni C, Marchetti M, Quaglini S, et. al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015 Feb;39(2):149-54. PubMed PMID: 24973057.

40: Ma Y, Ying X, Zou H, et. al. Cost-utility Analysis of Rhegmatogenous Retinal Detachment Surgery in Shanghai, China. Ophthalmic Epidemiol. 2015 Feb;22(1):13-9. Epub 2014 Feb 14. PubMed PMID: 24527711.

By CEA Registry Team on 2/10/2015 9:58 AM
By Peter Neumann, ScD, Joshua Cohen, PhD, Susan Parsons, MD, MRP, and Cayla Saret, BA
 
As discussed in a recent blog post, our new paper (1) in the journal Blood examined the cost-effectiveness of treatments for hematologic malignancies (blood cancers). The paper has received some media attention, including coverage in the Boston Business Journal, Healio HemOnc today, and Medical Xpress. The press coverage has emphasized that treatments for blood cancer provide “good value for money.”
 
It is important to emphasize several points as we do in the paper:
 
• This paper is a review of the existing peer-reviewed medical literature. The estimates come from published cost-effectiveness analyses. Moreover, the data are limited to studies cataloged in the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry, a repository of studies in the form of cost/quality-adjusted life years (QALYs).  We selected studies examining innovative treatments and excluded hematopoietic stem cell transplant, symptom management, and supportive care. These findings are limited by the small sample size. In addition, the literature may be subject to methodological issues or publication bias. For example, researchers conducting industry-funded studies may be more inclined to investigate interventions that are likely to demonstrate higher value and to report more favorable findings. We conducted a sub-analysis of non-industry funded studies, of which there were only seven. The non-industry funded studies reported a higher (less favorable) median ratio than industry funded studies. 
 
• Given the widespread discussion about the high prices of some of these interventions, we were somewhat surprised to find that many of the treatments appeared to be relatively cost-effective, even when we limited the sample to studies not funded by the pharmaceutical industry.
 
• Cost-effectiveness studies serve as one input for policymakers and stakeholders making decisions about investment, coverage, reimbursement, and so on. Other factors come into play, including but not limited to affordability, access, health impact, overall budget, and preferences. By reporting these results, we hope to encourage the consideration of value, in terms of the ratio of cost to effectiveness, as one tool in the decision-making process.
 
An appendix to the paper listing the 29 studies included in our review will be made available on the Blood web site shortly when the paper is published in its final form (subsequent to the currently available First Edition).
 
References
 
1.    Saret CJ, Winn A, Shah G, et. al. Value of Innovation in Hematologic Malignancies: A Systematic Review of Published Cost-Effectiveness Analyses. Blood 2015 First Edition.

 

By CEA Registry Team on 2/6/2015 9:39 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Rowland MR, Lesnock JL, Farris C, et. al. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced stage ovarian cancer in patients = 65 years old. Am J Obstet Gynecol. 2015 Jan 30. [Epub ahead of print] PubMed PMID: 25644442.

2: Mash R, Kroukamp R, Gaziano T, et. al. Cost-effectiveness of a diabetes group education program delivered by health promoters with a guiding style in underserved communities in Cape Town, South Africa. Patient Educ Couns. 2015 Jan  20. [Epub ahead of print] PubMed PMID: 25641665.

3: Mailhot Vega R, Kim J, Hollander A, et. al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015 Jan 29. [Epub ahead of print] PubMed PMID: 25641407.

4: Schuster A, Faulkner M, Zeymer U, et. al. Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial. Clin Res Cardiol. 2015 Jan 31. [Epub ahead of print] PubMed PMID: 25637294.

5: McEwan P, Ward T, Bennett H, et. al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One. 2015 Jan 30;10(1):e0117334. eCollection 2015. PubMed PMID: 25635922.

6: Black WC. Computed Tomography Screening for Lung Cancer in the National Lung Screening Trial: A Cost-effectiveness Analysis. J Thorac Imaging. 2015 Jan 29. [Epub ahead of print] PubMed PMID: 25635704.

7: Hagberg L, Hermansson L, Fredriksson C, et. al. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2015 Jan 30:1-6. [Epub ahead of print] PubMed PMID: 25634493.

8: Scalone L, Cortesi PA. Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years. BioDrugs. 2015 Jan 30. [Epub ahead of print] PubMed PMID: 25633571.

9: Moran AE, Odden MC, Thanataveerat A, et. al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015 Jan 29;372(5):447-55. PubMed PMID: 25629742.

10: Zachariah JP, Samnaliev M. Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model. J Med Econ. 2015 Jan 28:1-30. [Epub ahead of print] PubMed PMID: 25629653.

11: Roberts KJ, Sutton AJ, Prasad KR, et. al. Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases. Br J Surg. 2015 Jan 26. [Epub ahead of print] PubMed PMID: 25624168.

12: Palmer R, Cooper C, Enderby P, et. al. Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. Trials. 2015 Jan 27;16(1):18. [Epub ahead of print] PubMed PMID: 25623162.

13: Hunter R. Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England. Adv Ther. 2015 Jan;32(1):69-85. Epub 2015 Jan 27. PubMed PMID: 25620538.

14: Younossi ZM, Park H, Saab S, et. al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015 Jan 26. [Epub ahead of print] PubMed PMID: 25619871.

15: Wade R, Duarte A, Simmonds M, et. al. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Pharmacoeconomics. 2015 Jan 24. [Epub ahead of print] PubMed PMID: 25616671.

16: Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et. al. Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective? Radiother Oncol. 2015 Jan 20. [Epub ahead of print] PubMed PMID: 25616537.

17: Lønne G, Johnsen LG, Aas E, et. al. Comparing cost-effectiveness of X-stop to minimally Invasive Decompression in Lumbar Spinal Stenosis: A Randomized Controlled Trial. Spine (Phila Pa 1976). 2015 Jan 20. [Epub ahead of print] PubMed PMID: 25608246.

18: Tierney WM. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):387-8. PubMed PMID: 25607439.

19: Pinsky PF. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):387. PubMed PMID: 25607438.

20: Black WC, Keeler EB, Soneji SS. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):388. PubMed PMID: 25607437.

21: Haas M, De Abreu Lourenco R. Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness. Pharmacoeconomics. 2015 Jan 22. [Epub ahead of print] PubMed PMID: 25604096.

22: Kirsch F. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 20:1-16. [Epub ahead of print] PubMed PMID: 25600470.

23: Whitehurst DG, Bryan S, Lewis M, et. al. Implementing Stratified Primary care Management for low Back Pain: Cost Utility Analysis alongside a Prospective, Population-based, Sequential Comparison Study. Spine (Phila Pa 1976). 2015 Jan 16. [Epub ahead of print] PubMed PMID: 25599287.

24: Hansson E, Ekman I, Swedberg K, et. al. Person-centred care for patients with chronic heart failure - a cost-utility analysis. Eur J Cardiovasc Nurs. 2015 Jan 16. [Epub ahead of print] PubMed PMID: 25595358.

25: Aboagye E, Karlsson ML, Hagberg J, et. al. Cost-effectiveness of early interventions for non-specific low back pain: A randomized controlled study investigating medical yoga, exercise therapy and self-care advice. J Rehabil Med. 2015 Jan 27;47(2):167-73. PubMed PMID: 25403347.

By CEA Registry Team on 2/5/2015 10:07 AM

By Cayla Saret, BA and Peter Neumann, ScD

The costs of new treatments for hematologic malignancies (blood cancers) have provoked debate, such as the much-discussed piece in the journal Blood criticizing high prices for tyrosine kinase inhibitors for chronic myeloid leukemia. At times perspectives in this debate take into account only the cost of treatment or only the benefits, rather than both.

In a new paper also published in Blood, we and our colleagues investigated both the costs and benefits of innovative treatments across these cancers. We found that, though many of these treatments are associated with high costs, many are also associated with large benefits. Based on our analysis of the available literature, with some important caveats, many of these treatments may be cost-effective according to commonly used standards.

For our analysis, we included studies from the Tufts Cost-Effectiveness Analysis (CEA) Registry pertaining to innovative treatments for hematologic cancers. The CEA Registry includes studies that measure health benefits in quality-adjusted life years (QALYs), a measure that incorporates both length and quality of life. We found 29 studies (published 1996-2012) reporting 44 cost-effectiveness ratios, which we grouped into nine treatment agents and four cancer types. For each study, we extracted information about the study’s methodology, transparency, and a subjective quality rating. We examined cost-effectiveness ratios across the studies as well as within subgroups such as industry and non-industry-funded studies and studies that received a high quality rating.

Most cost-effectiveness ratios fell below (were more favorable than) the widely used $50,000/QALY or $100,000/QALY thresholds (73% and 86%, respectively). Industry-funded studies found a lower (more favorable) median ratio – $26,000/QALY – than non-industry-funded studies – $33,000/QALY.  This difference was not statistically significant. The distribution of cost-effectiveness ratios by value in the high quality studies (quality score ≥ 5 on a rating scale of 1-7, with 7 being the best) was similar to the overall distribution and not significantly different from the findings of the overall analysis.

Our study is limited by the small sample size of the studies. As with other studies based on published literature, findings may be subject to publication bias including selected conduct and reporting of studies. We limited our study to the cost-per-QALY literature and did not include other analyses such as cost-per-life year studies. In addition, cost-effectiveness ratios may have changed over time as associated costs or benefits have changed. For example, imatinib’s price increased to roughly three times its original price over about a decade.

In conclusion, our study suggests that many new treatments for these cancers may be cost-effective according to the published literature. Treatments appear to have both high prices and substantial health benefits in terms of quality-adjusted life years. Decision-makers may use cost-effectiveness as one factor among others (e.g. values, preferences, and affordability) when considering coverage for these and other interventions.

References

1.    Saret CJ, Winn A, Shah G, et. al. Value of Innovation in Hematologic Malignancies: A Systematic Review of Published Cost-Effectiveness Analyses. Blood 2015 First Edition.

By CEA Registry Team on 2/2/2015 4:11 PM

By James D. Chambers, Ph.D.

In a new paper published in Health Affairs, my colleagues and I examine whether Medicare coverage in national coverage determinations (NCDs) – the coverage pathway typically reserved for ‘big-ticket’ technologies – has become more restrictive over time.(1)

Using the Tufts Medical Center National Coverage Determination Database as our starting point, we developed a novel dataset of clinical evidence reviewed in NCDs and other factors known to influence decision making.(2)  We used logistic regression to examine whether coverage policy has changed over time when controlling for the quality of supporting clinical evidence and other factors. 

We found that when holding constant the level of supporting evidence, more recent coverage determinations (from mid-March 2008 through August 2012) were approximately twenty times less likely to be positive than earlier coverage determinations (from February 1999 through January 2002).  In other words, the evidentiary bar for medical intervention coverage under Medicare national coverage determinations became higher between 1999 and 2012.

We also found various characteristics of the clinical evidence and non-evidentiary decision inputs to be positively associated with coverage, including:

  • The number of patients in randomized controlled trials
  • The consistency of intervention-favorable findings among randomized controlled trials, among other clinical trials, and among clinical reviews
  • The consistency of favorable recommendations among clinical guidelines
  • The availability of alternative therapeutic approaches
  • The availability of cost-effectiveness evidence

Coverage policy is an important payer tool for promoting the appropriate use of medical interventions in the Medicare program.  However, rising evidence standards raise questions regarding patients’ access to new medical interventions and the challenges faced by manufacturers as they attempt to bring innovations to the market.

References:

  1. Chambers, JD, Chenoweth M, Cangelosi MJ, et. al. Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. Health Affairs 2015;34(2):253–260
  2. Chambers JD, Morris S, Neumann PJ, Buxton MJ.  Factors Predicting Medicare National Coverage: An Empirical Analysis. Med Care 2012; 50:249–256

 

By CEA Registry Team on 1/22/2015 10:09 AM

The Social Security Act established the Medicare program in 1965 to cover services “reasonable and necessary for diagnosis or treatment.” The first coverage for a preventive service (pneumococcal inoculation) under the program did not occur until Congressional action in 1980. Today, Medicare covers 23 preventive services.

Figure 1: Timeline of Preventative Services Covered for Medicare Beneficiaries
 


 
Click to view a larger image.

Read more about Medicare coverage of preventive services and the use of cost-effectiveness analysis in the blog post and the Health Policy paper.

References

1.    Chambers, JD, Cangelosi, MJ, Neumann, PJ. Medicare’s use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy 2014 Nov 22. [Epub ahead of print]

By CEA Registry Team on 1/20/2015 2:22 PM

By James Chambers, PhD

In a new paper published in Health Policy, my colleagues and I investigated the use of cost-effectiveness analysis (CEA) in Medicare coverage of prevention. We found that cost-effectiveness has played a longstanding role in coverage determinations for several preventive health services.  In contrast, no such consideration is used in coverage of treatments. While Medicare once dealt primarily with paying claims for treatments, preventative services have been gradually added to the program, with their addition becoming more commonplace over the past ten years. There has been little examination to date of the role CEA has played in coverage determinations for preventive measures.

When preventive services were initially added to the program, it was through Congressional action that required evidence of affordability. Of the 23 preventive services currently covered by Medicare, CEA played a role in coverage for nine. For example, CEA was used in coverage determinations for pneumococcal vaccine (1981), HIV screening (2010), and screening and behavioral counseling for alcohol misuse (2011). In addition, CEA was considered in multiple cases when Medicare decided not to cover a preventive service, e.g., screening computed tomography colonography (CTC) for colorectal cancer.

In other ways, the US has increasingly made efforts to promote preventive care – such as the addition of the annual wellness visit to the Medicare benefits package (2011).  However, by evaluating the cost-effectiveness of preventive services and not treatment, the government holds prevention to a stricter evidence standard.  Using CEA for prevention and not for treatment is a double standard. Expanding the role of CEA in Medicare coverage to include treatment would add balance and evidence to the process, and efficiency to the program.


References

1.    Chambers, JD, Cangelosi, MJ, Neumann, PJ. Medicare’s use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy 2014 Nov 22. [Epub ahead of print]

By CEA Registry Team on 1/16/2015 1:32 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Lee BY, Bartsch SM, Brown ST, et. al. Quantifying the Economic Value and Quality of Life Impact of Earlier Influenza Vaccination. Med Care. 2015 Jan 14. [Epub ahead of print] PubMed PMID: 25590676.

2: Romanus D, Cardarella S, Cutler D, et. al. Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Jan 14. [Epub ahead of print] PubMed PMID: 25590606.

3: Looker KJ, Wallace LA, Turner KM. Impact and cost-effectiveness of chlamydia testing in Scotland: a mathematical modelling study. Theor Biol Med Model. 2015 Jan 15;12(1):2. [Epub ahead of print] PubMed PMID: 25588390.

4: Stoddart A, van der Pol M, Pinnock H, et. al. Telemonitoring for chronic obstructive pulmonary disease: a cost and cost-utility analysis of a randomised controlled trial. J Telemed Telecare. 2015 Jan 13. [Epub ahead of print] PubMed PMID: 25586810.

5: Huxley N, Jones-Hughes T, Coelho H, et. al. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technol Assess. 2015 Jan;19(2):1-216. PubMed PMID: 25586547.

6: Grosse SD, Chaugule SS, Hay JW. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 14:1-17. [Epub ahead of print] PubMed PMID: 25585817.

7: Ross EL, Weinstein MC, Schackman BR, et. al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Jan 12. [Epub ahead of print] PubMed PMID: 25583979.

8: Wong WW, Tu HA, Feld JJ, et. al. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Jan 12. [Epub ahead of print] PubMed PMID: 25583667.

9: Quartuccio L, Di Bidino R, Ruggeri M, et. al. Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Jan 7. [Epub ahead of print] PubMed PMID: 25581074.

10: Gaudette É, Goldman DP, Messali A, et. al. Do Statins Reduce the Health and Health Care Costs of Obesity? Pharmacoeconomics. 2015 Jan 10. [Epub ahead of print] PubMed PMID: 25576147.

11: Kvamme MK, Lie E, Uhlig T, et. al. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford). 2015 Jan 7. [Epub ahead of print] PubMed PMID: 25573840.

12: Ang M, Nguyen HV, Kiew SY, et. al. Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis. Br J Ophthalmol. 2015 Jan 8. [Epub ahead of print] PubMed PMID: 25573149.

13: You JH, Lui G, Kam KM, et. al. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. J Infect. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25573001.

14: Zhang Z, Kolm P, Grau-Sepulveda MV, et. al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. J Am Coll Cardiol. 2015 Jan 6;65(1):1-11. PubMed PMID: 25572503.

15: Stollenwerk B, Bartmus T, Klug F, et. al. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model. Osteoporos Int.2015 Jan 9. [Epub ahead of print] PubMed PMID: 25572047.

16: Dick AW, Perencevich EN, Pogorzelska-Maziarz M, et. al. A decade of investment in infection prevention: A cost-effectiveness analysis. Am J Infect Control. 2015 Jan 1;43(1):4-9. PubMed PMID: 25564117.

17: Obreli-Neto PR, Marusic S, Guidoni CM, et. al. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. J Manag Care Spec Pharm. 2015 Jan;21(1):66-75. PubMed PMID: 25562774.

18: Delea TE, Amdahl J, Diaz J, et. al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015 Jan;21(1):46-54. PubMed PMID: 25562772.

19: Chen LA, Kim J, Boucher K, et. al. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecol Oncol. 2015 Jan 3. [Epub ahead of print] PubMed PMID: 25562668.

20: Shearer DW, Youm J, Bozic KJ. Short-term Complications Have More Effect on Cost-effectiveness of THA than Implant Longevity. Clin Orthop Relat Res. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25560958.

21: Minor T, Lasher A, Klontz K, et. al. The Per Case and Total Annual Costs of Foodborne Illness in the United States. Risk Anal. 2015 Jan 2. [Epub ahead of print] PubMed PMID: 25557397.

22: Hendriksen JM, Geersing GJ, van Voorthuizen SC, et. al. The cost-effectiveness of point-of-care D-dimer tests compared with a laboratory test to rule out deep venous thrombosis in primary care. Expert Rev Mol Diagn. 2015 Jan;15(1):125-36. PubMed PMID: 25537569.

23: D'Amico F, Rehill A, Knapp M, et. al. Maintenance cognitive stimulation therapy: an economic evaluation within a randomized controlled trial. J Am Med Dir Assoc. 2015 Jan 1;16(1):63-70. PubMed PMID: 25528281.

24: Gupta V, Baabbad R, Hammerby E, et. al. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2015 Jan 2:1-10. [Epub ahead of print] PubMed PMID: 25426701.

25: Revill PA, Walker S, Mabugu T, et. al. Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS. 2015 Jan 14;29(2):201-10. PubMed PMID: 25396263.

26: Rochau U, Sroczynski G, Wolf D, et. al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2015 Jan 14:1-11. [Epub ahead of print] PubMed PMID: 25393806.

27: Schackman BR, Leff JA, Barter DM, et. al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015 Jan;110(1):129-43. PubMed PMID: 25291977.

28: Beresniak A, Medina-Lara A, Auray JP, et. al. Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project. Pharmacoeconomics. 2015 Jan;33(1):61-9. PubMed PMID: 25230587.

29: Yu SY, Lee TJ, Jang SH, et. al. Cost-effectiveness of nationwide opportunistic screening program for dementia in South Korea. J Alzheimers Dis. 2015 Jan 1;44(1):195-204. PubMed PMID: 25208621.

30: Fleeman N, Bagust A, Beale S, et. al. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. Pharmacoeconomics. 2015 Jan;33(1):13-23. PubMed PMID: 25138171.

31: King CH. Health metrics for helminth infections. Acta Trop. 2015 Jan;141(PtB):150-60. Epub 2013 Dec 12. PubMed PMID: 24333545.

By CEA Registry Team on 1/5/2015 1:13 PM

By Peter Neumann, Sc.D. and Cayla Saret, B.A.

Cost-effectiveness thresholds, healthcare spending, quality-adjusted life years (QALYs)…we covered these topics and more in 2014. Here are some of our most popular posts of the past year. Follow us on Twitter and Facebook for updates.

1.       FDA considers draft guidance on FDAMA Section 114 (March 11): The Food and Drug Administration may offer further guidance on legislation that governs pharmaceutical companies’ promotion of health economic information.

2.       The curious resilience of the $50,000-per-QALY threshold (Aug 27): Researchers argue that multiple cost-effectiveness thresholds should replace the outdated $50,000-per-QALY metric.

3.       Cost-effectiveness analysis of personalized medicine: How much uncertainty is acceptable?: (Feb 27): Researchers debate the use of cost-effectiveness analysis for new genetic tests that may lack firm evidence of clinical effectiveness.

4.       Do specialty drugs offer value for money? (Oct 6): Specialty drugs may, in many cases, offer good value despite higher costs.

5.       Photo highlights from the CEVR symposium and celebratory dinner (Sept 22): In September, CEVR held a Symposium on Innovation and Cost-Effectiveness Research and a dinner to celebrate the CEA Registry’s 15th Anniversary.

6.       What are the returns of cancer research? Using QALYs to calculate IRR (Jul 16): One of the few papers to qualify the overall returns of medical research suggests “substantial” return for development of cancer-related interventions.

7.       Do PBM’s recent formulary restrictions point to an increased role for cost-effectiveness analysis in the US? (Aug 5): Changes in coverage policy by Express Scripts and CVS Caremark suggest that cost-effectiveness analysis may play a greater role in decisions by U.S. payers.

8.       Why the spike in new cost utility analyses in 2012? (March 27): Two possible explanations may illuminate why about 45% more cost-utility analyses were published in 2012 than 2011.

9.       What cost-effectiveness thresholds do US health economics cite most often? (Aug 28): While the $50,000-per-QALY threshold is commonly used, use of the $100,000-per-QALY benchmark is also increasing.

10.   A half century of US healthcare spending (Jul 24): A report by the California HealthCare Foundation provided insight into changes in healthcare spending in the last 50 years.

 

By CEA Registry Team on 1/5/2015 11:43 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Wen F, Yao K, Du ZD, et. al. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol. 2014 Dec 21;20(47):17976-84. PubMed PMID: 25548497.

2: Brettschneider C, Djadran H, Härter M, et. al. Cost-Utility Analyses of Cognitive-Behavioural Therapy of Depression: A Systematic Review. Psychother Psychosom. 2014 Dec 24;84(1):6-21. [Epub ahead of print] PubMed PMID: 25547334.

3: Tanaka E, Inoue E, Hoshi D, et. al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol.2014 Dec 30:1-31. [Epub ahead of print] PubMed PMID: 25547018.

4: Domínguez-Ortega J, Phillips-Anglés E, Barranco P, et. al. Cost-effectiveness of asthma therapy: A Comprehensive review. J Asthma. 2014 Dec 24:1-23. [Epub ahead of print] PubMed PMID: 25539023.

5: Huang YA, Lasry A, Hutchinson AB, et. al. A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States. Appl Health Econ Health Policy. 2014 Dec 25. [Epub ahead of print] PubMed PMID: 25536927.

6: Crespo C, Monleon A, Díaz W, et. al. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014 Dec 22;14(1):139. [Epub ahead of print] PubMed PMID: 25533141.

7: Gouveia M, Borges M, Trindade R, et. al. Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes. Rev Port Cardiol. 2014 Dec 16. [Epub ahead of print] English, Portuguese. PubMed PMID: 25528973.

8: Shiragami M, Mizukami A, Leeuwenkamp O, et. al. Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children. Infect Dis Ther. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25527448.

9: Hamid R, Loveman C, Millen J, et. al. Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. Pharmacoeconomics. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25526842.

10: Sawyer LM, Wonderling D, Jackson K, et. al. Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis. Pharmacoeconomics. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25526841.

11: Wu B, Li T, Cai J, et. al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014 Dec 19;14(1):984. PubMed PMID: 25526802.

12: Farag I, Howard K, Ferreira ML, et. al. Economic modelling of a public health programme for fall prevention. Age Ageing. 2014 Dec 18. [Epub ahead of print] PubMed PMID: 25523025.

13: Hole AR, Norman R, Viney R. RESPONSE PATTERNS IN HEALTH STATE VALUATION USING ENDOGENOUS ATTRIBUTE ATTENDANCE AND LATENT CLASS ANALYSIS. Health Econ. 2014 Dec 17. [Epub ahead of print] PubMed PMID: 25521533.

14: Kawasaki R, Akune Y, Hiratsuka Y, et. al. Cost-utility Analysis of Screening for Diabetic Retinopathy in Japan: A Probabilistic Markov Modeling Study. Ophthalmic Epidemiol. 2014 Dec 17:1-9. [Epub ahead of print] PubMed PMID: 25517603.

15: Offodile AC 2nd, Chatterjee A, Vallejo S, et. al. A Cost-Utility Analysis of the Use of Preoperative Computed Tomographic-Angiography in Abdomen-Based Perforator Flap Breast Reconstruction. Plast Reconstr Surg. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25517410.

16: Janzic A, Kos M. Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control. Pharmacoeconomics. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25512096.

17: Kongnakorn T, Lanitis T, Annemans L, et. al. Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clin Drug Investig. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25511639.

By CEA Registry Team on 12/19/2014 9:37 AM

By Paige Lin, Ph.D.

We collaborated on a new paper in Dementia and Cognitive Disorders EXTRA1 on neuropsychological measures that could predict the progression of Alzheimer’s disease (AD).  This study is unique because the analysis was drawn from real-world longitudinal patient data from the ALSOVA, a community-based study in Kuopio, Finland.  The study included 236 participants with mild cognitive impairment or mild AD at baseline, and assessed their cognitive function annually over a three-year follow-up period.  We examined which subtests of the Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Battery (CERAD-NB) were best correlated with disease progression, which was measured by the Clinical Dementia Rating scale Sum of Boxes (CDR-SB).  The CERAD-NB is a cognitive screening battery commonly used for the evaluation of suspected dementia.  In Finland, the CERAD-NB has been used in primary care. 

We found that the most predictive combination included verbal, visual and executive function measures, plus the Mini-Mental State Examination (MMSE).  This set of measures explained over 60% of the variation in AD progression.  The entire CERAD-NB typically takes 30 minutes to administer.  Our findings suggest that a shorter version of the CERAD-NB may provide a time-efficient alternative tool for evaluating AD patients’ cognitive declines in clinical care.


References

1.    Hallikainen I, Martikainen J, Lin P-J, et. al. The Progression of Alzheimer’s Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. Dementia and Geriatric Cognitive Disorders EXTRA 2014;4:494-508

By CEA Registry Team on 12/16/2014 1:25 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Ladabaum U, Mannalithara A, Jandorf L, et. al. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25492455.

2: Aballéa S, Maman K, Thokagevistk K, et. al. Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clin Drug Investig. 2014 Dec 10. [Epub ahead of print] PubMed PMID:25491433.

3: Nichols BE, Sigaloff KC, Kityo C, et. al. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc. 2014 Dec 5;17(1):19164. eCollection 2014. PubMed PMID: 25491351.

4: Delea TE, Amdahl J, Nakhaipour HR, et. al. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. Curr Oncol. 2014 Dec;21(6):e748-59. PubMed PMID: 25489263.

5: Delea TE, Amdahl J, Wang A, et. al. Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. Pharmacoeconomics. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25488880.

6: de Almeida JR, Moskowitz AJ, Miles BA, et. al. Transoral robotic surgery is cost-effective compared to (Chemo)radiotherapy for early t-classification oropharyngeal carcinoma: A cost-utility analysis. Head Neck. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25488048.

7: Sprague BL, Stout NK, Schechter C, et. al. Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts. Ann Intern Med. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25486550.

8: Rajan S, Baraniuk S, Parker S, et. al. Implementing a Mobile Stroke Unit Program in the United States: Why, How, and How Much? JAMA Neurol. 2014 Dec 8. [Epub ahead of print] PubMed PMID: 25485723.

9: Roze S, Saunders R, Brandt AS, et. al. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabet Med. 2014 Dec 6. [Epub ahead of print] PubMed PMID: 25483869.

10: Ebm CC, Sutton L, Rhodes A, et. al. Cost-Effectiveness in Goal-Directed Therapy: Are the Dollars Spent Worth the Value? J Cardiothorac Vasc Anesth. 2014 Dec;28(6):1660-1666. Review. PubMed PMID: 25479922.

11: McCann GA, Cohn DE, Jewell EL, et. al. Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecol Oncol. 2014 Dec 2. [Epub ahead of print] PubMed PMID: 25478927.

12: Fletcher JJ, Kotagal V, Mammoser A, et. al. Cost-Effectiveness of Transfers to Centers With Neurological Intensive Care Units After Intracerebral Hemorrhage. Stroke. 2014 Dec 4. [Epub ahead of print] PubMed PMID: 25477220.

13: Zhang W, Islam N, Ma C, et. al. Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. Pharmacoeconomics. 2014 Dec 5. [Epub ahead  of print] PubMed PMID: 25475964.

14: Raizer JJ, Fitzner KA, Jacobs DI, et. al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2014 Dec 2. [Epub ahead of print] PubMed PMID: 25466707.

15: Mather RC 3rd, Garrett WE, Cole BJ, et. al. Cost-effectiveness Analysis of the Diagnosis of Meniscus Tears. Am J Sports Med. 2014 Dec 1. [Epub ahead of print] PubMed PMID: 25451791.

16: Dilla T, Möller J, O Donohoe P, et. al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain: a cost-effectiveness comparison. BMC Psychiatry. 2014 Dec 2;14(1):298. [Epub ahead of print] PubMed PMID: 25438678.

17: Wu B, Song Y, Leng L, et. al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol. 2014 Dec 1. [Epub ahead of print] PubMed PMID: 25438197.

18: Mowatt G, Hernández R, Castillo M, et. al. Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2014 Dec;18(69):1-254. PubMed PMID: 25436855.

19: Weinstein JN, Tosteson AN, Tosteson TD, et. al. The SPORT Value Compass: Do the Extra Costs of Undergoing Spine Surgery Produce Better Health Benefits? Med Care. 2014 Dec;52(12):1055-63. PubMed PMID: 25334052.

20: Verhoef TI, Redekop WK, Hasrat F, et. al. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs. 2014 Dec;14(6):451-62. PubMed PMID: 25326294.

21: Rizzi CF, Ferraz MB, Poyares D, et. al. Quality-Adjusted Life-Years Gain and Health Status in Patients with OSAS after One Year of Continuous Positive Airway  Pressure Use. Sleep. 2014 Dec 1;37(12):1963-8. PubMed PMID: 25325505.

22: Wang Y, Xie F, Kong MC, et. al. Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2014 Dec;28(6):575-85. PubMed PMID: 25319314.

23: Lewis DJ, Attiah MA, Malhotra NR, Burnett MG, Stein SC. Anterior Surgical Management of Single-Level Cervical Disc Disease: A Cost-effectiveness Analysis. Spine (Phila Pa 1976). 2014 Dec 1;39(25):2084-92. PubMed PMID: 25271510.

24: Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W, Dorenkamp M. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014 Dec;32(12):2411-21. PubMed PMID: 25255395.

25: Thoma A, Kaur MN, Tsoi B, Ziolkowski N, Duku E, Goldsmith CH. Cost-effectiveness analysis parallel to a randomized controlled trial comparing vertical scar reduction and inverted T-shaped reduction mammaplasty. Plast Reconstr Surg. 2014 Dec;134(6):1093-107. PubMed PMID: 25255113.

26: Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. Pharmacoeconomics. 2014 Dec;32(12):1231-43. PubMed PMID: 25154747.

27: Vellopoulou A, van Agthoven M, van der Kolk A, de Knegt RJ, Berdeaux G, Cure S, Bianic F, Lamotte M. Cost Utility of Telaprevir-PR (Peginterferon-Ribavirin) Versus Boceprevir-PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Appl Health Econ Health Policy. 2014 Dec;12(6):647-59. PubMed PMID: 25103219.

28: Gladwell D, Henry T, Cook M, Akehurst R. Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK. Appl Health Econ Health Policy. 2014 Dec;12(6):611-22. PubMed PMID: 25086585.

29: Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec;32(12):1201-12. PubMed PMID: 25085219.

30: Castilla I, Mar J, Valcárcel-Nazco C, Arrospide A, Ramos-Goñi JM. Cost-utility analysis of gastric bypass for severely obese patients in Spain. Obes Surg. 2014 Dec;24(12):2061-8. PubMed PMID: 24913241.

By CEA Registry Team on 12/9/2014 1:38 PM

By Cayla Saret, B.A.

James Chambers, Ph.D. will participate in a TEDMED discussion later this week on addressing health costs. It is part of a series of TEDMED talks about Great Challenges – issues in health care that require imaginative design and complex solutions.  During the panel, entitled “A Delicate Balance: How Can We Rightsize Treatment Costs?” Dr. Chambers will speak in part about his Health Affairs paper published in October 2014. In this work, he investigated the costs and benefits of specialty drugs as compared with traditional drugs.

Other members of the panel include representatives from America’s Health Insurance Plans, the University of Michigan, the University of Chicago, and the Pharmaceutical Research and Manufacturers of America. The discussion will be moderated by Elisabeth Rosenthal, Senior Writer at the New York Times. 

The talk will be hosted online via a free Google+ Hangout on Thursday, December 11th at 12pm ET. RSVP here: https://plus.google.com/u/1/events/ckijf441fvujdq5nr3jtr912v2c?cfem=1.

By CEA Registry Team on 12/9/2014 1:01 PM

By Cayla Saret, B.A.

Dr. Peter Neumann will speak at the Summit on Real World Evidence hosted by healtheconomics.com on December 11th. In his presentation, Dr. Neumann will speak about the implications of the Food and Drug Administration Modernization Act of 1997 (FDAMA)’s Section 114 for the use of real world evidence to communicate evidence of value. The Section includes regulation for the promotion of health economics information, including certain types of real world data, to payers.

As we have discussed previously on this blog, the FDA indicated earlier this year that it was seeking public input for a draft guidance that would clarify its interpretation of the Section. We have also written about the lack of guidance in this field to date despite the growth of new approaches to analysis such as comparative effectiveness research (CER) and the use of real world data. In addition, we have argued for the expansion of the Section to include CER.

We believe that a draft guidance would provide much-needed clarity and an opportunity to address new methods that pharmaceutical companies may use to provide evidence of value to payers.

By CEA Registry Team on 12/1/2014 5:01 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Rozemeijer K, de Kok IM, Naber SK, et. al. Offering self-sampling to non-attendees of organized primary HPV screening: When do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev. 2014 Nov 28. [Epub ahead of print] PubMed PMID: 25432954.

2: Busnelli A, Papaleo E, Del Prato D, et. al. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum Reprod. 2014 Nov 28. [Epub ahead of print] PubMed PMID: 25432927.

3: Cheng HM, Pearson A, Sung SH, et. al. Cost-Effectiveness of Noninvasive Central Blood Pressure Monitoring in the Diagnosis of Hypertension. Am J Hypertens. 2014 Nov 27. [Epub ahead of print] PubMed PMID: 25430695.

4: Gupta V, Shafie AA, Baabbad R, et. al. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2014 Nov 26:1-30. [Epub ahead of print] PubMed PMID: 25426701.

5: Spackman E, Richmond S, Sculpher M, et. al. Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial. PLoS One. 2014 Nov 26;9(11):e113726. eCollection 2014. PubMed PMID: 25426637.

6: Gomez JA, Lepetic A, Demarteau N. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health. 2014 Nov 26;14(1):1222. [Epub ahead of print] PubMed PMID: 25424716.

7: Lachaine J, Mathurin K, Barakat S, et. al. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematol Oncol. 2014 Nov 25. [Epub ahead of print] PubMed PMID: 25424534.

8: You J, Ming WK, Chan P. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014 Nov 25;14(1):618. [Epub ahead of print] PubMed PMID: 25420713.

9: Loveman E, Copley VR, Colquitt JL, et. al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014 Nov 19;15:63. PubMed PMID: 25410822.

10: Ribeiro RA, Duncan BB, Ziegelmann PK, et. al. Cost-Effectiveness of High, Moderate and Low-Dose Statins in the Prevention of Vascular Events in the Brazilian Public Health System. Arq Bras Cardiol. 2014 Nov 18;0:0. [Epub ahead of print] Portuguese, English. PubMed PMID: 25409878.

11: Round J, Leurent B, Jones L. A cost-utility analysis of a rehabilitation service for people living with and beyond cancer. BMC Health Serv Res. 2014 Nov 19;14(1):558. [Epub ahead of print] PubMed PMID: 25407558.

12: Walleser Autiero S, Hallas N, Betts C, et. al. The cost-effectiveness of sacral nerve stimulation for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2014 Nov 19. [Epub ahead of print] PubMed PMID: 25407358.

13: Home P, Baik SH, Gálvez GG, et. al. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes. J Med Econ. 2014 Nov 21:1-11. [Epub ahead of print] PubMed PMID: 25407031.

14: Mensch A, Stock S, Stollenwerk B, et. al. Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation. Pharmacoeconomics. 2014 Nov 18. [Epub ahead of print] PubMed PMID: 25404426.

15: Blank PR, Filipits M, Dubsky P, et. al. Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics. 2014 Nov 18. [Epub ahead of print] PubMed PMID: 25404424.

16: Neumann A, Mostardt S, Biermann J, et. al. Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clin Res Cardiol. 2014 Nov 18. [Epub ahead of print] PubMed PMID: 25403774.

17: Javanbakht M, Bakhsh RY, Mashayekhi A, et. al. CORONARY BYPASS SURGERY VERSUS PERCUTANEOUS CORONARY INTERVENTION: COST-EFFECTIVENESS IN IRAN: A STUDY IN PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASE. Int J Technol Assess Health Care. 2014 Nov 17:1-8. [Epub ahead of print] PubMed PMID: 25401422.

18: Barocas DA, Bensink ME, Berry K, et. al. ECONOMIC EVALUATION OF DIAGNOSTIC LOCALIZATION FOLLOWING BIOCHEMICAL PROSTATE CANCER RECURRENCE. Int J Technol Assess Health Care. 2014 Nov 17:1-9. [Epub ahead of print] PubMed PMID: 25399914.

19: Levy AN, García A Ruiz AJ, García-Agua Soler N, et. al. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2014 Nov 24:1-6. [Epub ahead of print] PubMed PMID: 24995661.

By CEA Registry Team on 11/17/2014 4:45 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Hsieh HM, Tsai SL, Shin SJ, et. al. Cost-Effectiveness of Diabetes Pay-for-Performance Incentive Designs. Med Care. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25397966.

2: Sax PE, Sypek A, Berkowitz BK, et. al. HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? PLoS One. 2014 Nov 14;9(11):e113031. eCollection 2014. PubMed PMID: 25397616.

3: Maggiolo F, Di Matteo S, Bruno G, et. al. Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status. J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19798.eCollection 2014. PubMed PMID: 25397542.

4: Revill PA, Walker S, Mabugu T, et. al. Opportunities for improving the efficiency of paediatric HIV treatment programmes: lessons from the ARROW trial. AIDS. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25396263.

5: Petrou S, Boland A, Khan K, et. al. ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN. Int J Technol Assess Health Care. 2014 Nov 14:1-7. [Epub ahead of print] PubMed PMID: 25394502.

6: Bennette CS, Gallego CJ, Burke W, et. al. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25394171.

7: Peng S, Tafazzoli A, Dorman E, et. al. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19605.  eCollection 2014. PubMed PMID: 25394109.

8: Oddershede L, Walker S, Paton N, et. al. Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19498. eCollection 2014. PubMed PMID: 25394007.

9: Rochau U, Sroczynski G, Wolf D, et. al. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leuk Lymphoma. 2014 Nov 13:1-40. [Epub ahead of print] PubMed PMID: 25393806.

10: Reynolds MR, Apruzzese P, Galper BZ, et. al. Cost-Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial. J Am Heart Assoc. 2014 Nov 11;3(6). PubMed PMID: 25389284.

11: Huh WK, Williams E, Huang J, et. al. Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening. Appl Health Econ Health Policy. 2014 Nov 11. [Epub ahead of print] PubMed PMID: 25385310.

12: Borgström F, Beall DP, Berven S, et. al. Health economic aspects of vertebral augmentation procedures. Osteoporos Int. 2014 Nov 8. [Epub ahead of print] PubMed PMID: 25381046.

13: Lehnert T, Streltchenia P, Konnopka A, et. al. Health burden and costs of obesity and overweight in Germany: an update. Eur J Health Econ. 2014 Nov 8. [Epub ahead of print] PubMed PMID: 25381038.

14: Sørensen J, Primdahl J, Horn H, et. al. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial. Scand J Rheumatol. 2014 Nov 7:1-9. [Epub ahead of print] PubMed PMID: 25380077.

15: Ziakas PD, Zacharioudakis IM, Zervou FN, et. al. Methicillin-Resistant Staphylococcus aureus Prevention Strategies in the ICU: A Clinical Decision Analysis. Crit Care Med. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25377019.

16: Black WC, Gareen IF, Soneji SS, et. al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014 Nov 6;371(19):1793-802. PubMed PMID: 25372087.

17: Wright D, Twigg M, Thornley T. Chronic obstructive pulmonary disease case finding by community pharmacists: a potential cost-effective public health intervention. Int J Pharm Pract. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25371146.

18: Henry TL, De Brouwer BF, Van Keep MM, et. al. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2014 Nov 7:1-12. [Epub ahead of print] PubMed PMID: 25367314.

19: Varier RU, Biltaji E, Smith KJ, et. al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect. 2014 Nov 3. [Epub ahead of print] PubMed PMID: 25366338.

20: Jutkowitz E, Choi HK, Pizzi LT, et. al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014 Nov 4;161(9):617-26. doi: 10.7326/M14-0227. PubMed PMID: 25364883.

21: Olgiati P, Bajo E, Serretti A; C.E.A.P (Cost-Effectiveness Analysis on Psychiatric Disorders) - group. Benefit of slow titration of paroxetine to treat  depression in the elderly. Hum Psychopharmacol. 2014 Nov;29(6):544-51. Epub 2014 Nov 3. PubMed PMID: 25363240.

22: Cangelosi MJ, Ortendahl JD, Meckley LM, et. al. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Rev Pharmacoecon Outcomes Res. 2014 Nov 1:1-8. [Epub ahead of print] PubMed PMID: 25363000.

23: Lewis MA, Bann CM, Karns SA, et. al. Cross-site evaluation of the alliance to reduce disparities in diabetes: clinical and patient-reported outcomes. Health Promot Pract. 2014 Nov;15(2 Suppl):92S-102S. PubMed PMID: 25359255.

24: Bae YH, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Pharm. 2014 Nov;20(11):1086-92. PubMed PMID: 25351969.

25: Palmieri V, Baldi C, Di Blasi PE, et. al. Impact of DRG billing system on health budget consumption in percutaneous treatment of mitral valve regurgitation in heart failure. J Med Econ. 2014 Nov 4:1-7. [Epub ahead of print] PubMed PMID: 25350644.

26: Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany. J Med Econ. 2014 Nov 11:1-11. [Epub ahead of print] PubMed PMID: 25348011.

27: Attard CL, Pepper AN, Brown ST, et. al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2014 Nov 10:1-16. [Epub ahead of print] PubMed PMID: 25347449.

28: Claxton L, Malcolm B, Taylor M, et. al. Ranibizumab, Verteporfin  Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging. 2014 Nov;31(11):837-48. PubMed PMID: 25300507; PubMed Central PMCID: PMC4210643.

29: Tassie E, Scotland G, Brittenden J, et. al. Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. Br J Surg. 2014 Nov;101(12):1532-40. PubMed PMID: 25274220.

30: Negrón ME, Kaplan GG, Barkema HW, et. al. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. Inflamm Bowel Dis. 2014 Nov;20(11):2046-55.PubMed PMID: 25230162.

31: McAnany SJ, Overley S, Baird EO, et. al. The 5-Year Cost-effectiveness of Anterior Cervical Discectomy and Fusion and Cervical Disc Replacement: A Markov Analysis. Spine (Phila Pa 1976). 2014 Nov 1;39(23):1924-33. PubMed PMID: 25188602.

32: Paulden M, O'Mahony JF, Culyer AJ, et. al. Some Inconsistencies in NICE's Consideration of Social Values. Pharmacoeconomics. 2014 Nov;32(11):1043-53. PubMed PMID: 25145802.

33: Zueger PM, Schultz NM, Lee TA. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics. 2014 Nov;32(11):1079-91. PubMed PMID: 25052903.

By CEA Registry Team on 11/3/2014 2:22 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Wong FK, So C, Chau J, et. al. Economic evaluation of the differential benefits of home visits with telephone calls and telephone calls only in transitional discharge support. Age Ageing. 2014 Oct 29. [Epub ahead of print] PubMed PMID: 25355620.

2: Lachaine J, Mathurin K, Barakat S, et. al. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Eur J Haematol. 2014 Oct 29. [Epub ahead of print] PubMed PMID: 25354894.

3: Vallejo-Torres L, Castilla I, González N, et. al. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2014 Oct 30:1-12. [Epub ahead of print] PubMed PMID: 25354790.

4: Brosa M, García Del Muro X, Mora J, et. al. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct 29:1-10. [Epub ahead of print] PubMed PMID: 25354299.

5: Coward S, Heitman SJ, Clement F, et. al. Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation. Am J Gastroenterol. 2014 Oct 28. [Epub ahead of print] PubMed PMID: 25350768.

6: Palmieri V, Baldi C, Di Blasi PE, et. al. Impact of DRG Billing System on Health Budget Consumption in Percutaneous Treatment of Mitral Valve Regurgitation in Heart Failure. J Med Econ. 2014 Oct 28:1-20. [Epub ahead of print] PubMed PMID: 25350644.

7: Brecker S, Mealing S, Padhiar A, et. al. Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart. 2014 Oct 23;1(1):e000155. eCollection 2014. PubMed PMID: 25349700.

8: Levin LA, Husberg M, Sobocinski PD, et. al. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace. 2014 Oct 27. [Epub ahead of print] PubMed PMID: 25349228.

9: Mihalopoulos C, Magnus A, Lal A, et. al. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs. Aust N Z J Psychiatry. 2014 Oct 27. [Epub ahead of print] PubMed PMID: 25348698.

10: Pietzsch JB, Liu S, Garner AM, et. al. Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. Sleep. 2014 Oct 28.[Epub ahead of print] PubMed PMID: 25348126.

11: Walter E, Odin P. Cost-effectiveness of continuous subcutaneous Apomorphine in the treatment of Parkinson´s Disease in the UK and Germany. J Med Econ. 2014 Oct 28:1-36. [Epub ahead of print] PubMed PMID: 25348011.

12: Attard C, Pepper A, Brown S, et. al. Cost-effectiveness Analysis of Neoadjuvant Pertuzumab and Trastuzumab Therapy for Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer in Canada. J Med Econ. 2014 Oct 27:1-38. [Epub ahead of print] PubMed PMID: 25347449.

13: McEwan P, Bennett H, Ward T, et. al. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. Pharmacoeconomics. 2014 Oct 26. [Epub ahead of print] PubMed PMID: 25344660.

14: Trenaman L, Sadatsafavi M, Almeida F, et. al. Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea: A Case Study. Med Decis Making. 2014 Oct 24. [Epub ahead of print] PubMed PMID: 25344130.

15: Peels DA, Hoogenveen RR, Feenstra TL, et. al. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial. BMC Public Health. 2014 Oct 23;14(1):1099. [Epub ahead of print] PubMed PMID: 25342517.

16: Aronsson M, Walfridsson H, Janzon M, et. al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2014 Oct 23. [Epub ahead of print] PubMed PMID: 25341739.

17: Oppong R, Jowett S, Nicholls E, et. al. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials. Rheumatology (Oxford). 2014 Oct 21. [Epub ahead of print] PubMed PMID: 25339642.

18: Shepard DS, Halasa YA, Fonseca DM, et. al. Economic evaluation of an area-wide integrated pest management program to control the asian tiger mosquito in new jersey. PLoS One. 2014 Oct 22;9(10):e111014. eCollection 2014. PubMed PMID: 25338065.

19: Kalra VB, Wu X, Forman HP, et. al. Cost-Effectiveness of Angiographic Imaging in Isolated Perimesencephalic Subarachnoid Hemorrhage. Stroke. 2014 Oct 21. [Epub ahead of print] PubMed PMID: 25336513.

20: Weinstein JN, Tosteson AN, Tosteson TD, et. al. The SPORT Value Compass: Do the Extra Costs of Undergoing Spine Surgery Produce Better Health Benefits? Med Care. 2014 Oct 20. [Epub ahead of print] PubMed PMID: 25334052.

21: Huang H, Taylor DC, Carson RT, et. al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ. 2014 Oct 21:1-31. [Epub ahead of print] PubMed PMID: 25333331.

22: You J. Antimicrobial stewardship programs - cost-minimizing or cost-effective? Expert Opin Pharmacother. 2014 Oct 21:1-3. [Epub ahead of print] PubMed PMID: 25331093.

23: Ising HK, Smit F, Veling W, et. al. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychol Med. 2014 Oct 21:1-12. [Epub ahead of print] PubMed PMID: 25330734.

24: Ma Y, Ying X, Zou H, et. al. Rhegmatogenous Retinal Detachment Surgery in Elderly People over 70 Years Old: Visual Acuity, Quality of Life, and Cost-Utility Values. PLoS One. 2014 Oct 17;9(10):e110256. eCollection 2014. PubMed PMID: 25330168.

25: Pan Y, Chen Q, Zhao X, et. al.; TIMS-CHINA investigators. Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China. PLoS One. 2014 Oct 20;9(10):e110525. eCollection 2014. PubMed PMID: 25329637.

26: Liu S, Watcha D, Holodniy M, et. al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014 Oct 21;161(8):546-53. PubMed PMID: 25329202.

27: Fortney JC, Pyne JM, Burgess JF Jr. Population-Level Cost-Effectiveness of Implementing Evidence-Based Practices into Routine Care. Health Serv Res. 2014 Oct 18. [Epub ahead of print] PubMed PMID: 25328029.

28: Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, et. al. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct 18:1-14. [Epub ahead of print] PubMed PMID: 25327502.

By CEA Registry Team on 10/16/2014 1:25 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Westwood M, van Asselt T, Ramaekers B, et. al. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014 Oct;18(62):1-132. PubMed PMID: 25314637.

2: Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014 Oct;12(10):1417-25. PubMed PMID: 25313181.

3: San Miguel R, Gimeno-Ballester V, Blázquez A, et. al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2014 Oct 13. [Epub ahead of print] PubMed PMID: 25311032.

4: Stanczyk NE, Smit ES, Schulz DN, et. al. An economic evaluation of a video- and text-based computer-tailored intervention for smoking cessation: a cost-effectiveness and cost-utility analysis of a randomized controlled trial. PLoS One. 2014 Oct 13;9(10):e110117.eCollection 2014. PubMed PMID: 25310007.

5: Lamb SE, Williamson EM, Heine PJ, et. al. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet. 2014 Oct 9. [Epub ahead of print] PubMed PMID: 25308290.

6: Price D, Keininger D, Costa-Scharplatz M, et. al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med. 2014 Oct 2. [Epub ahead of print] PubMed PMID: 25307414.

7: Christensen H, Trotter CL, Hickman M, et. al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014 Oct 9;349:g5725. PubMed PMID: 25301037.

8: Claxton L, Malcolm B, Taylor M, et. al. Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging. 2014 Oct 10. [Epub ahead of print] PubMed PMID: 25300507.

9: Livingston G, Barber J, Rapaport P, et. al. START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia. Health Technol Assess. 2014 Oct;18(61):1-242. PubMed PMID: 25300037.

10: Liu JY, You RX, Guo M, et. al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther. 2014 Oct 8. [Epub ahead of print] PubMed PMID: 25299636.

11: Hsu WK, Hashimoto RE, Berven SH, et. al. Biological Substitutes/Extenders for Spinal Arthrodesis: Which Agents Are Cost-effective? Spine (Phila Pa 1976). 2014 Oct 15;39(22 Suppl 1):S86-98. PubMed PMID: 25299264.

12: Harrop JS, Hilibrand A, Mihalovich KE, et. al. Cost-effectiveness of Surgical Treatment for Degenerative Spondylolisthesis and Spinal Stenosis. Spine (Phila Pa 1976). 2014 Oct 15;39(22 Suppl 1):S75-85. PubMed PMID: 25299263.

13: Yan X, Hu HT, Liu S, et. al. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Neurol Res. 2014 Oct 8:1743132814Y0000000447. [Epub ahead of print] PubMed PMID: 25297471.

14: Schackman BR, Leff JA, Barter DM, et. al. Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2014 Oct 8. [Epub ahead of print] PubMed PMID: 25291977.

15: Chambers JD, Thorat T, Pyo J, et. al. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014 Oct 1;33(10):1751-60. PubMed PMID: 25288419.

16: Bonastre J, Marguet S, Lueza B, et. al. Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. J Clin Oncol. 2014 Oct 6. [Epub ahead of print] PubMed PMID: 25287824.

17: Chen A, Dowdy DW. Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. PLoS One. 2014 Oct 6;9(10):e108742. eCollection 2014. PubMed PMID: 25285793.

18: Swart E, Makhni EC, Macaulay W, et. al. Cost-effectiveness analysis of fixation options for intertrochanteric hip fractures. J Bone Joint Surg Am. 2014 Oct 1;96(19):1612-20. PubMed PMID: 25274786.

19: Evans M, Wolden M, Gundgaard J, et. al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2014 Oct 1:1-34. [Epub ahead of print] PubMed PMID: 25271378.

20: Lundqvist C, Beiske AG, Reiertsen O, et. al. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. J Neurol. 2014 Oct 1. [Epub ahead of print] PubMed PMID: 25270681.

21: Luciano JV, D Amico F, Cerdà-Lafont M, et. al. Cost-utility of cognitive behavioural therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomised controlled trial. Arthritis Res Ther. 2014 Oct 1;16(5):451. [Epub ahead of print] PubMed PMID: 25270426.

22: Lee WS, Parks NA, Garcia A, et. al. Pan computed tomography versus selective computed tomography in stable, young adults after blunt trauma with moderate mechanism: A cost-utility analysis. J Trauma Acute Care Surg. 2014 Oct;77(4):527-33. PubMed PMID: 25250590.

23: Kongnakorn T, Lanitis T, Annemans L, et. al. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in belgium. Clin Drug Investig. 2014 Oct;34(10):709-21. PubMed PMID: 25164005.

24: van Hees F, Zauber AG, Klabunde CN, et. al. The appropriateness of more intensive colonoscopy screening than recommended in medicare beneficiaries: a modeling study. JAMA Intern Med. 2014 Oct 1;174(10):1568-76. PubMed PMID: 25133641.

25: Alali AS, Naimark DM, Wilson JR, et. al. Economic evaluation of decompressive craniectomy versus barbiturate coma for refractory intracranial hypertension following traumatic brain injury*. Crit Care Med. 2014 Oct;42(10):2235-43. PubMed PMID: 25054675.

26: Tran-Duy A, Boonen A, Kievit W, et. al. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 2014 Oct;32(10):1015-28. PubMed PMID: 24972589.

27: Lairson DR, Parikh RC, Cormier JN, et. al. Cost-Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13. PubMed PMID: 24920195.

28: Zafari Z, Thorlund K, FitzGerald JM, et. al. Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. Pharmacoeconomics. 2014 Oct;32(10):995-1004. PubMed PMID: 24920194.

29: Refaat T, Choi M, Gaber G, et. al. Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. Am J Clin Oncol. 2014 Oct;37(5):480-5. PubMed PMID: 23388565.

Please view the blog archive for earlier entries

Search This Blog